The Chinese-German Journal of Clinical Oncology

, Volume 11, Issue 9, pp 539–543 | Cite as

Treatment for triple-negative breast cancer

  • Xuebing Shi
  • Lu WangEmail author


Triple-negative breast cancers (TNBCs) neither express estrogen receptor and progesterone receptor nor overexpress human epidermal growth factor receptor-2. Because of the special molecular features, triple-negative breast cancer is not either sensitive to endocrine therapy or targeted therapy of trastuzumab. There has not been standard treatment regimen for triple-negative breast cancer yet and chemotherapy has still been the chief therapy currently. However, with the great progress of oncology and molecular biology, the understanding of the natural history, pathophysiology and molecular features of this disease has been greatly improved, and a growing number of novel and effective therapies and discoveries of new biological targets for this phenotype of breast cancers have been reported, which provide new insights into therapeutic strategies for the women suffering from it.

Key words

triple-negative breast neoplasms therapy review 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 2007, 109: 1721–1728.PubMedCrossRefGoogle Scholar
  2. 2.
    Yamamoto Y, Ibusuki M, Kawasoe T, et al. Basal cell-like signature is an independent prognostic factor in triple-negative breast cancer. J Clin Oncol, 2008, 26: 22184.Google Scholar
  3. 3.
    Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 2008, 26: 1275–1281.PubMedCrossRefGoogle Scholar
  4. 4.
    Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res, 2005, 11: 5678–5685.PubMedCrossRefGoogle Scholar
  5. 5.
    Nunes JS, Tsunoda AT, Viana LS, et al. Analysis of response to neoadjuvant chemotherapy (NCT) with doxorubicin plus cyclophosphamide followed by paclitaxel (AC-T) in triple negative locally advanced breast cancer (LABC) in Brazil. J Clin Oncol, 2008, 26: 11551.Google Scholar
  6. 6.
    Chang HR, Glaspy J, Allison MA, et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer, 2010, 116: 4227–4237.PubMedCrossRefGoogle Scholar
  7. 7.
    Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol, 2006, 59: 729–735.PubMedCrossRefGoogle Scholar
  8. 8.
    Steponaviciene L, Lachej-Mikeroviene N, Smailyte G, et al. Triple negative breast cancer: adjuvant chemotherapy effect on survival. Adv Med Sci, 2011, 56: 285–290.PubMedCrossRefGoogle Scholar
  9. 9.
    Königsberg R, Pfeiler G, Kurzawa R, et al. Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients. Cancer Invest, 2011, 29: 180–186.PubMedCrossRefGoogle Scholar
  10. 10.
    Kashiwagi S, Yashiro M, Takashima T, et al. Advantages of adjuvant chemo -therapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res, 2011, 13: R122.PubMedCrossRefGoogle Scholar
  11. 11.
    Gluz O, Nitz UA, Harbeck N, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol, 2008, 19: 861–870.PubMedCrossRefGoogle Scholar
  12. 12.
    Chia JW, Ang P, See H, et al. Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination Chemotherapy. J Clin Oncol, 2007, 25: 1086.Google Scholar
  13. 13.
    Zaniboni A, Meriggi F, Rizzi A, et al. Navelbine (N), leucovorin (L), and fluorouracil (5-FU) (FLN) for triple-negative metastatic breast cancer (TNBC). J Clin Oncol 2008, 26: 1127.Google Scholar
  14. 14.
    Maisano R, Zavettieri M, Azzarello D, et al. Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study. J Chemother, 2011, 23: 40–43.PubMedGoogle Scholar
  15. 15.
    Ozkan M, Berk V, Kaplan MA, et al. Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience. Neoplasma. 2012, 59: 38–42.PubMedCrossRefGoogle Scholar
  16. 16.
    Chen Y, Wang ZY, Yao Y, et al. The effect and side effects of Gem-citabine plus Vinorelbine in patients with triple-negative metastatic breast cancer. Chinese-German J Clin Oncol, 2009, 8: 557–560.CrossRefGoogle Scholar
  17. 17.
    Haffty BG, Yang Q, Reiss M, et al. Locoregional and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 2006, 24: 5652–5657.PubMedCrossRefGoogle Scholar
  18. 18.
    Wang J, Shi M, Ling R, et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiother Oncol, 2011, 100: 200–204.PubMedCrossRefGoogle Scholar
  19. 19.
    Comen E, Davids M, Kirchhoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women. Breast Cancer Res Treat, 2011, 129: 185–190.PubMedCrossRefGoogle Scholar
  20. 20.
    Lee E, McKean-Cowdin R, Ma H, et al. Characteritics of triple-negative breast cancer in patients with a BRCA1 mutation:results from a population-based study of young women. J Clin Oncol, 2011, 29: 4373–4380.PubMedCrossRefGoogle Scholar
  21. 21.
    Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst, 2004, 96: 1659–1668.PubMedCrossRefGoogle Scholar
  22. 22.
    El Guerrab A, Zegrour R, Nemlin CC, et al. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One, 2011, 6: e25080.PubMedCrossRefGoogle Scholar
  23. 23.
    Deng XS, Wang S, Deng A, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle, 2012, 11: 367–376.PubMedCrossRefGoogle Scholar
  24. 24.
    Moon HG, Hwang KT, Kim JA, et al. NFIB is a potential target for estrogen receptor-negative breast cancers. Mol Oncol, 2011, 5: 538–544.PubMedCrossRefGoogle Scholar
  25. 25.
    Tryfonopoulos D, Walsh S, Collins DM, et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol, 2011, 22: 2234–2240.PubMedCrossRefGoogle Scholar
  26. 26.
    Föst C, Duwe F, Hellriegel M, et al. Targeted chemotherapy for triplenegative breast cancers via LHRH receptor. Oncol Rep, 2011, 25: 1481–1487.PubMedGoogle Scholar
  27. 27.
    King TD, Suto MJ, Li Y. The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem, 2012, 113: 13–18.PubMedCrossRefGoogle Scholar
  28. 28.
    O’shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med, 2011, 364: 205–214.PubMedCrossRefGoogle Scholar
  29. 29.
    Zeng Q, Yang Z, Gao YJ, et al. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo biolumine -scence imaging study. Eur J Cancer, 2010, 46: 1132–1143.PubMedCrossRefGoogle Scholar
  30. 30.
    Rainville C, Khan Y, Tisman G. Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J, 2009, 2: 8390.PubMedCrossRefGoogle Scholar
  31. 31.
    Harputluoglu H, Dizdar O, Karaahmet F, et al. Vitamin D intake may be effective in the management of triple-negative breast cancer. J BUON, 2011, 16: 569.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Medical OncologyYijishan Hospital of Wannan Medical CollegeWuhuChina

Personalised recommendations